Evolus Inc
NASDAQ:EOLS 9:36:06 AM EDT
Other Pre-Announcement
Jeuveau Demonstrates Effects Lasting 26 Weeks In Interim Phase II Data Results
Published: 01/28/2023 13:09 GMT
Evolus Inc (EOLS) - "extra-strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase Ii Data Results, Representing Prolonged 6-month Performance.
Results Indicate a Favorable Safety Profile; No Serious Adverse Events Reported and 88% of All Adverse Events Were Mild.
Trial Completion Expected Mid-2023; Final Results Anticipated to Be Presented in 2h 2023.
Results Indicate a Favorable Safety Profile; No Serious Adverse Events Reported and 88% of All Adverse Events Were Mild.
Trial Completion Expected Mid-2023; Final Results Anticipated to Be Presented in 2h 2023.